Edition:
United Kingdom

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

2.98USD
6:02pm BST
Change (% chg)

$0.12 (+4.20%)
Prev Close
$2.86
Open
$2.86
Day's High
$3.00
Day's Low
$2.86
Volume
306,131
Avg. Vol
382,091
52-wk High
$5.05
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.17
Wednesday, 8 May 2019 

May 8 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.17.Q1 EARNINGS PER SHARE ESTIMATE $-0.22 -- REFINITIV IBES DATA.REMAINS ON TRACK TO ACHIEVE 125 HOSPITAL FORMULARY APPROVALS BY END OF 2019..ACELRX PHARMACEUTICALS - QUARTERLY COMBINED RESEARCH AND DEVELOPMENT AND SG&A EXPENSE FOR REMAINING QUARTERS OF 2019 IS EXPECTED TO REMAIN IN RANGE OF $15 MILLION TO $18 MILLION.  Full Article

Acelrx Pharmaceuticals Reports Q4 Loss Per Share Of $0.18
Thursday, 7 Mar 2019 

March 7 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF DSUVIA AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.Q4 EARNINGS PER SHARE ESTIMATE $-0.20 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $105.7 MILLION AS OF DECEMBER 31, 2018.2019 ANNUAL DEBT SERVICE IS EXPECTED TO APPROXIMATE $9 MILLION.2019 ANNUAL CAPITAL EXPENDITURES ARE EXPECTED TO RANGE FROM $5-$7 MILLION.QTRLY COMBINED RESEARCH AND DEVELOPMENT AND SG&A EXPENSE IN 2019 IS EXPECTED TO RANGE FROM $15 MILLION TO $18 MILLION, DEPENDING ON QUARTER.INCREASING EXPECTED NUMBER OF FORMULARY APPROVAL WINS BY END OF 2019 TO 125.  Full Article

AcelRx Pharmaceuticals Q2 Loss Per Share $0.20
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.20.Q2 EARNINGS PER SHARE VIEW $-0.20 -- THOMSON REUTERS I/B/E/S.  Full Article

AcelRx Prices Public Offering Of 7.27 Mln Shares At $2.75/Share
Thursday, 12 Jul 2018 

July 12 (Reuters) - AcelRx Pharmaceuticals Inc ::ACELRX PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.27 MILLION COMMON SHARES PRICED AT $2.75PER SHARE.  Full Article

Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry Ventures
Wednesday, 23 May 2018 

May 23 (Reuters) - AcelRx Pharmaceuticals Inc ::THREE ARCH'S SHARES OF ACELRX COMMON STOCK ACQUIRED IN A PRIVATE TRANSACTION LED BY LEERINK REVELATION PARTNERS AND INDUSTRY VENTURES.ACELRX PHARMACEUTICALS INC - NO CHANGES WERE MADE TO COMPOSITION OR SIZE OF ACELRX'S BOARD OF DIRECTORS.ACELRX PHARMACEUTICALS - ALL OF CO'S SHARES OWNED BY THREE ARCH ACQUIRED BY INVESTORS LED BY LEERINK REVELATION PARTNERS, INDUSTRY VENTURES.ACELRX PHARMACEUTICALS INC - REMAIN ON TRACK TO ACHIEVE REMAINING KEY MILESTONES THIS YEAR.ACELRX PHARMACEUTICALS INC - THREE ARCH FUNDS IN DISSOLUTION PROCESS AND ARE EACH FINALIZING LIQUIDATION OF THEIR ENTIRE RESPECTIVE PORTFOLIOS.ACELRX PHARMACEUTICALS INC - THREE ARCH FUNDS REMAINING ASSETS COMPRISED OF 9.4 MILLION SHARES IN AGGREGATE ACROSS ALL OF FUNDS.  Full Article

Acelrx Pharmaceuticals posts Q3 loss of $0.28 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Acelrx Pharmaceuticals Inc :Acelrx pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.28.Q3 revenue $1.5 million.Q3 revenue view $2.2 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Acelrx pharmaceuticals - $67.9 million of cash and cash equivalents at Sseptember 30, 2017​.  Full Article

AcelRx Pharma receives Complete Response Letter from the FDA for Dsuvia™ NDA
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Acelrx Pharmaceuticals Inc :AcelRx Pharmaceuticals receives Complete Response Letter from the FDA for Dsuvia™ NDA.AcelRx - ‍CRL states that FDA determined it cannot approve NDA in its present form and provides recommendations needed for resubmission​.AcelRx Pharmaceuticals Inc - ‍confirm plans to move towards resubmission of Dsuvia NDA​.AcelRx Pharmaceuticals Inc - ‍AcelRx ended Q3 with an estimated $67.9 million in cash and we will provide further financial updates on our Q3 earnings call​.AcelRx Pharmaceuticals-will request a meeting with FDA to discuss topics covered in CRL.AcelRx Pharmaceuticals Inc - ‍ received a complete response letter from FDA regarding its new drug application for Dsuvia, 30 MCG​.AcelRx - in CRL, collection of additional data requested on at least 50 patients to assess safety of dsuvia dosed at maximum amount set in proposed labelling​.AcelRx Pharmaceuticals Inc - ‍in CRL, FDA recommended certain changes to directions for use to address use-related errors, including dropped tablets​.  Full Article